263021-30-3

Basic information

• Product Name: N-BOC-4-(METHYLAMINO)BENZOIC ACID
• Synonyms: N-BOC-4-(METHYLAMINO)BENZOIC ACID;BOC-4-METHYLAMINOBENZOIC ACID;Benzoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]methylamino]- (9CI);4-N-Boc-N-MethylaMinobenzoic Acid;4-(N-Boc-MethylaMino)benzoic acid, 97%;4-[(tert-Butoxycarbonyl)- (Methyl)aMino]benzoic Acid;4-[[(1,1-DiMethylethoxy)carbonyl]MethylaMino]benzoic Acid;4-[N-(tert-Butoxycarbonyl)-N-MethylaMino]benzoic Acid
• CAS NO: 263021-30-3
• Molecular Formula: C₁₃H₁₇NO₄
• Molecular Weight: 251.28
• Product Categories: N-BOC;Amines;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 263021-30-3.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: N-BOC-4-(METHYLAMINO)BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-4-(METHYLAMINO)BENZOIC ACID(263021-30-3)
• EPA Substance Registry System: N-BOC-4-(METHYLAMINO)BENZOIC ACID(263021-30-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-52-43
• Safety Statements: 26-36/37/39-36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 263021-30-3(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 263021-30-3 differently. You can refer to the following data:
1. An intermediate for Methotrexate (M260675) derivatives as antitumor agents.
2. 4-(N-Boc-methylamino)benzoic acid is used as pharmaceutical intermediate.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 10541-83-0 N-methyl-p-aminobenzoic acid 
• 619-45-4 4-methoxycarbonyl aniline 
• 74-88-4 methyl iodide 

Downstream Products

• 1196987-72-0 {4-[5-(3-benzyloxy-phenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-methyl-carbamic acid tert-butyl ester 
• 1097196-59-2 allyl 4-(methylamino)benzoate hydrochloride 
• 1196987-74-2 {4-[5-(3-hydroxy-phenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-methyl-carbamic acid tert-butyl ester 
• 780821-17-2 (4-formylphenyl)(methyl)carbamic acid tert-butyl ester 
• 1294501-78-2 C₁₄H₉⁽³⁾H₃FN₃O 
• 1201323-66-1 [4-(5-fluorooxazolo[5,4-b]pyridin-2-yl)phenyl]methylamine 
• 168830-93-1 tert-butyl (4-(bromomethyl)phenyl)(methyl)carbamate 
• 442910-11-4 C₂₁H₂₃N₇O₃ 
• 442909-23-1 7-(2-furyl)-3-(4-(N-methylamino)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 
• 1201324-14-2 C₁₃H₁₆ClNO₃ 
• 863666-25-5 N-benzyloxy-4-[methyl-(4-phenyl-butyryl)-amino]-benzamide 
• 863666-18-6 N-benzyloxy-4-methylamino-benzamide 
• 863666-14-2 (4-benzyloxycarbamoyl-phenyl)-methyl-carbamic acid tert-butyl ester 

Relevant articles and documents

Novel Potent Dopamine-Norepinephrine and Triple Reuptake Uptake Inhibitors Based on Asymmetric Pyran Template and Their Molecular Interactions with Monoamine Transporters

We have carried out a structural exploration of (2S,4R,5R)-2-(bis(4-fluorophenyl)methyl)-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol (D-473) to investigate the influence of various functional groups on its aromatic ring, the introduction of heteroc

Substituted Pyran Derivatives

Certain 3,6-disubstituted and 2, 4, 5-trisubstituted pyran derivatives that exhibit potent activity on monoamine transport systems are provided. The 3, 6 and 2, 4, 5 pyrans are useful in probing the effects of their binding to monoamine transporter system

Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors

Previously, we developed a strategy to develop a novel class of histone deacetylase (HDAC) inhibitors by tethering short-chain fatty acids with Zn 2+-chelating motifs, which led to N-hydroxy-4-(4-phenylbutyryl-amino) benzamide (HTPB), a hydroxa